WuXi Advanced Therapies (WuXi ATU), the advanced therapies business unit of WuXi AppTec, is a Contract Testing Development and Manufacturing Organization (CTDMO) that offers integrated platforms to transform the discovery, development, testing, manufacturing and commercialization of cell and gene therapies. The company offers its customers an end-to-end solution for cell and gene therapy development, spanning early pre-clinical discovery to GMP manufacture and commercial lot release.
View the paper in full here.
WuXi ATU’s headquarters are located in Philadelphia’s Navy Yard. In recent years, the CTDMO has expanded to add plasmid, viral vector and cell therapy manufacturing and testing facilities in Wuxi City and Shanghai, a research facility in Oxford through the acquisition of OXGENE in 2021, and it also recently entered a collaboration with the A*STAR Biotechnology Institute in Singapore.
In this Q&A, WuXi ATU’s chief executive officer, David Chang, discusses some of these key recent events, as well as cultivating a culture of success and general market trends impacting contract organizations operating in the cell and gene space.